FIRST AMENDMENT TO CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • November 4th, 2021 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This First Amendment to Contingent Value Rights Agreement (this “Amendment”) dated as of November 1, 2021 (the “Amendment Effective Date”), is entered into by and among Oncternal Therapeutics, Inc. (F/K/A GTx, Inc.), a Delaware corporation (“Parent”), Marc S. Hanover, as representative of Holders (“Holders’ Representative”), and Computershare Inc., as Rights Agent, and amends that certain Contingent Value Rights Agreement dated as of June 7, 2019 by and among Parent, Holders’ Representative and Rights Agent (the “Agreement”). Capitalized terms used herein without definition have the meanings provided to such terms in the Agreement.
